CN107337710A - A kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition - Google Patents
A kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition Download PDFInfo
- Publication number
- CN107337710A CN107337710A CN201710620163.3A CN201710620163A CN107337710A CN 107337710 A CN107337710 A CN 107337710A CN 201710620163 A CN201710620163 A CN 201710620163A CN 107337710 A CN107337710 A CN 107337710A
- Authority
- CN
- China
- Prior art keywords
- pro
- active peptide
- antihypertensive
- pharmaceutical composition
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 38
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 17
- 241001122767 Theaceae Species 0.000 abstract description 16
- 230000036772 blood pressure Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 206010020772 Hypertension Diseases 0.000 abstract description 12
- 238000003304 gavage Methods 0.000 abstract description 9
- 125000000266 alpha-aminoacyl group Chemical group 0.000 abstract description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract description 5
- 230000001631 hypertensive effect Effects 0.000 abstract description 5
- 206010010356 Congenital anomaly Diseases 0.000 abstract description 4
- 230000037396 body weight Effects 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- -1 aminoacyl proline methyl esters Chemical class 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000005352 clarification Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108010025306 histidylleucine Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940026510 theanine Drugs 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 3
- 229960000830 captopril Drugs 0.000 description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 2
- HQEIPVHJHZTMDP-JEDNCBNOSA-N methyl (2s)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCCN1 HQEIPVHJHZTMDP-JEDNCBNOSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 1
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229910002114 biscuit porcelain Inorganic materials 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition.The amino acid sequence of the active peptide is：Tea aminoacyl tea aminoacyl proline, there is structure shown in Formulas I.The IC of Angiotensin-Converting (ACE) activity suppression of active peptide of the present invention50For 0.92 μm of ol/L, minimum point 152mmHg is dropped to from 187mmHg using blood pressure after congenital Hypertensive Rats of the dosage gavage of 1.5mg/kg body weight 2.5 hours, the constant drug effect time is 3.5 hours.
Description
Technical field
The invention belongs to biomedicine field, more particularly, to a kind of antihypertensive active peptide The-The-Pro and answers
With, and a kind of antihypertensive pharmaceutical composition.
Background technology
《Chinese cardiovascular disease report 2015》Point out that the cardiovascular disease illness rate in China is in and continue ascent stage.Hypertension
Be angiocardiopathy Major Risk Factors into common recognition, it be the promotion that persistently rises of China's angiocardiopathy illness rate because
Element.Ministry of Public Health's statistics in 2014 shows that the hypertension sufferer rate in China is 25.5%, and some provinces reach 27.9%, the whole nation
Hyperpietic's number is estimated up to 2.7 hundred million.
At present, many drugs for hypertension are considered as the medicine of a clinical line, wherein Angiotensin-Converting
Inhibitor (ACEI) is the best medicine of clinical effectiveness, as how general enalapril, captopril, Benazepril, lisinopril, group be
Profit etc..But they still have certain side effect, such as dry cough, fash, angioedema and injury of kidney.
ACEI class medicines are a kind of peptides and modified amino acid class material, and natural albumen is abundant peptide resource.Cause
This, scientists are endeavoured to prepare ACEI active peptides by the way of enzyme hydrolysis and fermentation always, to make hyperpietic
Benefit.As two have anti-hypertension bioactivity tripeptides " VPP " (Val-Pro-Pro, VPP) and " IPP " (Ile-Pro-Pro,
IPP) it is accredited out.But this preparation method cost is high, repeatability is low, bioavailability is low, there is an urgent need to develop one kind
New replacement production technology.These researchs are all based on the peptide information that contains in protein, although with the increase of peptide molecular weight,
Its structure will be varied, activity will also have a potentiality further, but the molecular sieving effect due to intestinal mucosa is rich in it
Peptase, constrain and utilize native protein activity development of resources ACEI peptides small-molecule substances.Therefore, chemical modification peptide how is evaded
The side effect of class or amino acids ACEI small-molecule drugs and avoid internal peptase hydrolysis and absorbed intact, turn into exploitation safety
The ACEI small-molecule drug study hotspots having no side effect.
The content of the invention
It is an object of the invention to provide a kind of antihypertensive active peptide The-The-Pro and application and pharmaceutical composition.
The first aspect of the present invention is to provide a kind of antihypertensive active peptide The-The-Pro, the amino of the active peptide
Acid sequence is：Tea aminoacyl-tea aminoacyl-proline, there is structure shown in Formulas I.Referred to as The-The-Pro (Theanine
(The)-Theanine(The)-Proline(Pro))。
The active feature request to forming amino acid residue of the invention according to anti-hypertension ACEI class peptide molecules, i.e., it is quantitative
Feature rare amino acid in structure-activity relationship (QSAR), and common food plant tea, different order is analyzed by molecular docking
Binding ability between the tri-peptide molecule and Angiotensin-Converting (ACE) molecule of amino acid residue combination, primarily determines that tool
There is antihypertensive peptide molecule, prepared by liquid phase synthesizing method, further verified by vitro and in vivo bioactivity, screening is true
The fixed synthetic peptide with stronger antihypertensive active.The antihypertensive active peptide can be made by the conventional method of this area, example
Such as liquid phase synthesizing method.
The second aspect of the present invention provides described antihypertensive active peptide The-The-Pro and is preparing antihypertensive medicine
Application in product and food.
The third aspect of the present invention provides a kind of antihypertensive pharmaceutical composition, including active ingredient and auxiliary material, described
Active ingredient include described antihypertensive active peptide The-The-Pro.
According to the present invention, the auxiliary material can be conventional various pharmaceutic adjuvants or food additives.
The present invention has following advantage compared with prior art：
The present invention proposes a kind of different active peptide.Prior art passes through external proteolysis or micro- from native protein
Biofermentation separation obtains active peptide, can further be hydrolyzed by the peptase being rich in intestinal mucosa, and it is actual in vivo to reduce it
Effect.The active peptide of the present invention is made up of rare amino acid and conventional amino acid, in native protein and is not present such sequence
Row are formed.Therefore, active peptide of the invention can escape the further hydrolysis of vivo protein enzyme, ensure that its integrality absorbed
The stability acted in vivo.
The IC of Angiotensin-Converting (ACE) activity suppression of active peptide of the present invention50For 0.92 μm of ol/L, use
The congenital Hypertensive Rats of dosage gavage of 1.5mg/kg body weight after 2.5 hours blood pressure drop to minimum point from 187mmHg
152mmHg, constant drug effect time are 3.5 hours.
Other features and advantages of the present invention will be described in detail in subsequent specific embodiment part.
Brief description of the drawings
Exemplary embodiment of the invention is described in more detail in conjunction with the accompanying drawings, it is of the invention above-mentioned and its
Its purpose, feature and advantage will be apparent.
Fig. 1 is The-The-Pro to congenital hypertensive rat blood pressure function analysis laboratory test results figure.
Embodiment
With reference to specific embodiment, the present invention will be further described in detail, but the invention is not restricted to following implementation
Example.In following examples, when being not particularly illustrated, " % " refers both to mass percent.
Embodiment 1
The synthesis of The-The-Pro tripeptides.Antihypertensive active peptide of the present invention can be synthesized by artificial chemistry, specific behaviour
Make as follows：
Polypeptide of the present invention is synthesized using Liquid phase peptides synthesis method, by a certain amount of N- tertbutyloxycarbonyls theanine methyl esters
(Boc-The-OH) inserted with proline methyl ester hydrochloride (H-Pro-Ome.HCl) in round-bottomed flask, add dimethylformamide
(DMF) clarification is dissolved to, N-methyl morpholine (NMM) and dicyclohexylcarbodiimide (DCC) is continuously added, is gently mixed, instead
It should stay overnight.
Further, above-mentioned reaction solution is filtered by vacuum, ethyl acrylate (EA) and H is added in filtrate2O is carried out
Chromatography.Supernatant liquid is drawn, using NaHCO3/H2O is washed 2 times, then with citric acid/H2O is washed 2 times, the washing of saturation NaCl solution
2 times, Na2SO4Dry, the grease that Rotary Evaporators are evaporated acquisition is N- tertbutyloxycarbonyl tea aminoacyl proline methyl esters (Boc-
The-Pro-Ome)。
Further, 4N hydrogen chloride gas/ethyl acrylate, dissolving are added in N- tertbutyloxycarbonyl tea aminoacyl proline methyl esters
To clarification, reaction 2 hours is stirred at room temperature.Add the absolute ether of 6-8 times of volume while stirring in reaction solution, chromatographed,
4000rpm is centrifuged 3 minutes.Ether repeated washing is used after abandoning supernatant 5 times, and precipitation obtains white solid matter and be dried in vacuo
To tea aminoacyl proline methyl ester hydrochloride (H-The-Pro-Ome.HCl).
Further, by a certain amount of N- tertbutyloxycarbonyls theanine methyl esters (Boc-The-OH) and tea aminoacyl proline first
Ester hydrochloride (H-The-Pro-Ome.HCl) is inserted in round-bottomed flask, is added dimethylformamide (DMF) and is dissolved to clarification, after
It is continuous to add N-methyl morpholine (NMM) and dicyclohexylcarbodiimide (DCC), it is gently mixed, reaction is overnight.
Further, confirm whether reaction is complete by thin-layer chromatography (TCL).Above-mentioned reaction solution is filtered by vacuum,
Ethyl acrylate (EA) and H are added in filtrate2O is chromatographed.Supernatant liquid is drawn, using NaHCO3/H2O is washed 2 times, then
With citric acid/H2O is washed 2 times, and saturation NaCl solution is washed 2 times, Na2SO4Dry, Rotary Evaporators are evaporated the grease of acquisition
For N- tertbutyloxycarbonyl tea aminoacyl tea aminoacyl proline methyl esters (Boc-The-The-Pro-Ome).
Further, in N- tertbutyloxycarbonyl tea aminoacyl tea aminoacyl proline methyl esters (Boc-The-The-Pro-Ome)
Add methanol (MeOH) and tetrahydrofuran (THF) (1:1) solution is stirred reaction, and lithium hydroxide is added after solution clarification
(LiOH)/H2O regulation pH ≈ 13, are kept for 2 hours, confirm whether reaction is complete by thin-layer chromatography (TCL).Reaction solution is inserted
Separatory funnel, add polyethylene terephthalate (PET) and wash 2 times repeatedly, interception lower floor liquid.Add in lower floor's liquid
Enter ethyl acrylate, after 2N HCl regulation solution to acidity, be placed in separatory funnel layering, it is true by thin-layer chromatography (TCL)
Recognize, intercept supernatant liquid.By supernatant liquid citric acid/H2O is washed 2 times, and saturation NaCl solution is washed 2 times, Na2SO4Dry,
The grease that Rotary Evaporators are evaporated acquisition is N- tertbutyloxycarbonyl tea aminoacyl tea aminoacyl proline (Boc-The-The-Pro-
OH)。
4N hydrogen chloride gas/the third is added in N- tertbutyloxycarbonyl tea aminoacyl tea aminoacyl proline (Boc-The-The-Pro-OH)
Olefin(e) acid ethyl ester, clarification is dissolved to, reaction 2 hours is stirred at room temperature.Add the anhydrous second of 6-8 times of volume while stirring in reaction solution
Ether, chromatographed, 4000rpm is centrifuged 3 minutes.Ether repeated washing is used after abandoning supernatant 5 times, and precipitation obtains white solid matter and entered
Row vacuum drying obtains tea aminoacyl tea aminoacyl proline tripeptides (The-The-Pro) semifinished product.
Further, semifinished product passes through semi-preparative reverse-phase high performance liquid chromatography (reversed-phase column：30 × 250 millimeters of Yi Lite
C18 posts；Mobile phase (acetonitrile of A liquid 100% (ACN), B liquid 100%H2O), linear gradient 14%~80%；The ml/min of flow velocity 3
Clock) eluting peak is separated and collected, it is standby after freezing.
Embodiment 2
Extracorporeal blood vessel Converting Enzyme (ACE) active suppression test.
Horse urea acyl histidyl- leucine (hippuryl-L-histidyl-L-leucine, HHL) is under the catalysis of ACE enzymes
Fast decoupled produces hippuric acid (Hippuric Acid, HA) and dipeptides histidyl-leucine (HL), adds ACE enzyme levels
After agent, the activity of ACE enzymes is suppressed, and HA and HL growing amount are reduced, and ACE is extracted by rabbit lung in the present embodiment, enzyme activity
For 0.76mU/mL, developed the color by DAB, HA growing amounts are determined using spectrophotometer method, analyze ACE enzyme activity.Ethyl acetate extracts
Hippuric acid in reactant, then reacted in acetic anhydride with the pyridine solution (DAB developers) containing paradime thylaminobenzaldehyde
Bisque compound is generated, directly in its OD value of 459nm colorimetric estimations, ACE enzyme inhibitors are evaluated to ACE enzymes by following equation
Inhibiting rate.Concentration (the IC of required synthesis tripeptides is suppressed with 50% ACE enzymatic activitys50) define the ACE suppressions for synthesizing tripeptides
System activity.
ACE inhibitory activity (%)=[(ODcontrol-ODsample)/(ODcontrol-ODblank)] × 100%
Specific reaction system and condition are shown in Table 1
Table 1
The present embodiment method measures the active kyrine of the present invention to ACE inhibitory activity IC50For 0.92 μm of ol/L.
Embodiment 3
The internal drop test of congenital Hypertensive Rats (SHR).
Using SoftronBP-98A type rat intelligence non-invasive blood pressure instruments, the systolic pressure for covering tail method measure measure rat is utilized
(SBP)。
Under SHR rats (spontaneous hypertensive rat) waking state, mouse is placed in mouse bag first, keeps constant temperature,
The method for using SoftronBP-98A type rat intelligence non-invasive blood pressure instruments cover tail measure tail vein blood pressure, determines rat
Systolic pressure (SBP).Start to determine the blood pressure of rat every other day in experiment the last week, start experimental record after the stable adaptation of rat.
The rat blood pressure before gavage is first determined, then 1.5mg/kg body weight doses carry out sample (active kyrine of embodiment 1, The-
The-Pro) gavage, the isometric physiological saline of blank control group gavage (Saline), drug control group gavage 10mg/kg body weight
Drug for hypertension captopril (captopril) is carried out continuously monitoring of blood pressure 4 hours, every 30 minutes continuous notes after sample gavage
Record rat blood pressure.Each test point determines the blood pressure of 3 rats, and the interval time determined every time about 1 is analyzed, and takes 3 measure
Blood pressure of the average value of value as the test point rat, as a result as shown in Figure 1.
Fig. 1 is after saline control group, drug for hypertension control group and synthesizing activity peptide group rat oral gavage are administered
Blood pressure situation, its data measured carry out system processing with SPSS system softwares, using the t methods of inspection.Can by experimental result
Know, compared with drug control group, the pressure reduction effect of synthetic peptide is more sluggish 30 minutes or so than medicine group, while Effect time is relatively
It is short, about 3.5 hours.For synthesizing activity peptide gavage after 2.5 hours, SHR blood pressures dropped significantly to minimum point, in gavage 4 hours
Afterwards, blood pressure rises are to initial pressure value.Illustrate that active peptide of the present invention (The-The-Pro) has preferable blood pressure lowering effect.
It is described above various embodiments of the present invention, described above is exemplary, and non-exclusive, and
It is not limited to disclosed each embodiment.In the case of without departing from the scope and spirit of illustrated each embodiment, for this skill
Many modifications and changes will be apparent from for the those of ordinary skill in art field.
Claims (4)
1. a kind of antihypertensive active peptide The-The-Pro, it is characterised in that the amino acid sequence of the active peptide is：Tea ammonia
Acyl-tea aminoacyl-proline, there is structure shown in Formulas I：
2. the antihypertensive active peptide The-The-Pro described in claim 1 is in antihypertensive medicine and food is prepared
Using.
3. a kind of antihypertensive pharmaceutical composition, including active ingredient and auxiliary material, it is characterised in that described active ingredient bag
Include antihypertensive active peptide The-The-Pro as claimed in claim 1.
4. pharmaceutical composition according to claim 3, wherein, the auxiliary material is pharmaceutic adjuvant or food additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710620163.3A CN107337710A (en) | 2017-07-26 | 2017-07-26 | A kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710620163.3A CN107337710A (en) | 2017-07-26 | 2017-07-26 | A kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107337710A true CN107337710A (en) | 2017-11-10 |
Family
ID=60216587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710620163.3A Pending CN107337710A (en) | 2017-07-26 | 2017-07-26 | A kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107337710A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111848729A (en) * | 2019-04-30 | 2020-10-30 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl asparagine and glutamine |
| CN112694429A (en) * | 2020-12-29 | 2021-04-23 | 江苏医药职业学院 | Polypeptide and application thereof in preparing ACE inhibitor or blood pressure lowering product |
| CN113461773A (en) * | 2021-08-05 | 2021-10-01 | 湖北泓肽生物科技有限公司 | Liquid phase synthesis method of LKP tripeptide |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1612892A (en) * | 2001-11-21 | 2005-05-04 | 森永乳业株式会社 | Novel peptide having angiotensin convertase inhibitory effect |
| CN1623600A (en) * | 2003-12-04 | 2005-06-08 | 中国科学院大连化学物理研究所 | Inhibitor of angiotensin I transferase activity and its application |
| CN1899278A (en) * | 2005-07-21 | 2007-01-24 | 陈建操 | Theanine used for preparing medicine/health product for treating depression |
| CN101022737A (en) * | 2004-07-22 | 2007-08-22 | 格罗伯斯卵类科学有限公司 | Anti-hypertensive functional food products |
| US20070253941A1 (en) * | 2006-04-28 | 2007-11-01 | Naidu A Satyanarayan | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
| CN101305017A (en) * | 2005-06-08 | 2008-11-12 | 康斯乔最高科学研究公司 | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same |
| CN102399262A (en) * | 2010-09-07 | 2012-04-04 | 任发政 | Tripeptides with angiotensin converting enzyme inhibition activity and their use and composition |
| CN104159912A (en) * | 2012-03-09 | 2014-11-19 | 森永乳业株式会社 | Dipeptidyl peptidase-iv inhibitor |
| CN105001139A (en) * | 2015-07-08 | 2015-10-28 | 南京葆赫生物技术有限公司 | Antihypertensive active peptide, preparation method thereof and application thereof |
| CN105017122A (en) * | 2015-07-08 | 2015-11-04 | 南京葆赫生物技术有限公司 | Anti-hypertension bioactive peptide, preparation method and application thereof |
-
2017
- 2017-07-26 CN CN201710620163.3A patent/CN107337710A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1612892A (en) * | 2001-11-21 | 2005-05-04 | 森永乳业株式会社 | Novel peptide having angiotensin convertase inhibitory effect |
| CN1623600A (en) * | 2003-12-04 | 2005-06-08 | 中国科学院大连化学物理研究所 | Inhibitor of angiotensin I transferase activity and its application |
| CN101022737A (en) * | 2004-07-22 | 2007-08-22 | 格罗伯斯卵类科学有限公司 | Anti-hypertensive functional food products |
| CN101305017A (en) * | 2005-06-08 | 2008-11-12 | 康斯乔最高科学研究公司 | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same |
| CN1899278A (en) * | 2005-07-21 | 2007-01-24 | 陈建操 | Theanine used for preparing medicine/health product for treating depression |
| US20070253941A1 (en) * | 2006-04-28 | 2007-11-01 | Naidu A Satyanarayan | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
| CN102399262A (en) * | 2010-09-07 | 2012-04-04 | 任发政 | Tripeptides with angiotensin converting enzyme inhibition activity and their use and composition |
| CN104159912A (en) * | 2012-03-09 | 2014-11-19 | 森永乳业株式会社 | Dipeptidyl peptidase-iv inhibitor |
| CN105001139A (en) * | 2015-07-08 | 2015-10-28 | 南京葆赫生物技术有限公司 | Antihypertensive active peptide, preparation method thereof and application thereof |
| CN105017122A (en) * | 2015-07-08 | 2015-11-04 | 南京葆赫生物技术有限公司 | Anti-hypertension bioactive peptide, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| HIDEHIKOYOKOGOSHI，MIKIKOBAYASHI: "Hypotensive effect of γ-glutamylmethylamide in spontaneously hypertensive rats", 《LIFE SCIENCES》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111848729A (en) * | 2019-04-30 | 2020-10-30 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl asparagine and glutamine |
| CN111848729B (en) * | 2019-04-30 | 2022-06-24 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl asparagine and glutamine |
| CN112694429A (en) * | 2020-12-29 | 2021-04-23 | 江苏医药职业学院 | Polypeptide and application thereof in preparing ACE inhibitor or blood pressure lowering product |
| CN113461773A (en) * | 2021-08-05 | 2021-10-01 | 湖北泓肽生物科技有限公司 | Liquid phase synthesis method of LKP tripeptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103052717B (en) | Industrial production method for producing antihypertensive bioactive peptide | |
| EP1648922B1 (en) | Spatially-defined macrocyclic compounds useful for drug discovery | |
| CN104561207B (en) | The double enzymolysis preparation method of spirulina antitumor polypeptide | |
| CN104450839B (en) | The preparation method of the rice bran protein peptide with ACE inhibitory activity | |
| CN107337710A (en) | A kind of antihypertensive active peptide The The Pro and application and pharmaceutical composition | |
| CN107312064A (en) | A kind of antihypertensive active peptide GABA The Pro and application and pharmaceutical composition | |
| CN105001139B (en) | A kind of antihypertensive active peptide, its preparation method and application | |
| CN107964034B (en) | The ultrasonic wave added simulation digestion method of casein active peptide and health food application | |
| CN105017122B (en) | A kind of antihypertensive active peptide, its preparation method and application | |
| CN112552394B (en) | Yak antihypertensive peptide and preparation method thereof | |
| CN112625088A (en) | Preparation method and application of mussel ACE inhibitory peptide | |
| CN110669122B (en) | Preparation method of zein anti-inflammatory polypeptide | |
| CN107337712A (en) | A kind of antihypertensive active peptide Orn Hyp Pro and application and pharmaceutical composition | |
| CN107325153A (en) | A kind of antihypertensive active peptide Citn Hyp Pro and application and pharmaceutical composition | |
| CN107337711A (en) | A kind of antihypertensive active peptide Citn Pro Hyp and application and pharmaceutical composition | |
| CN107964040A (en) | The ultrasonic wave added simulation digestion method of lactoglobulin active peptide and functional food application | |
| CN108003229B (en) | Zein ACE inhibitory peptide and application thereof as health-care food | |
| CN102558298A (en) | Method for synthesizing tetrapeptide isomers by using solid phase peptide synthesis method and applications of tetrapeptide isomers | |
| CN102786580A (en) | Antihypertensive active peptide IVP | |
| CN102786579A (en) | Antihypertensive active peptide VIP | |
| CN104894198A (en) | Preparation method of hypoallergenic total-nutrient oyster active peptide | |
| CN106749524A (en) | A kind of anti-fat heptapeptide NPVWKRK | |
| CN111105845B (en) | Preparation of antihypertensive peptide based on protein folding fingerprint bar code design | |
| CN114891065B (en) | Blood sugar-reducing sea cucumber peptide with alpha-amylase inhibitory activity and preparation method and application thereof | |
| CN106518971A (en) | Anti-obesity decapeptide CANPHELPNK |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171110 |
|
| RJ01 | Rejection of invention patent application after publication |